Rob Bresnahan
Rob Bresnahan (R-PA) bought $15K-$50K of $AMD (Advanced Micro Devices, Inc. (AMD)) on May 15, 2025, part of 44 transactions in this filing (20 buys, 24 sells).
HillSignal flagged 5 timing concerns on this filing — trades that line up closely with related legislative or contract activity.
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Showing the 6 largest positions. See every transaction in the table below.
Suspicious Timing Detected
5 flagsRep. Rob Bresnahan bought $1,001 - $15,000 in $CAT on 2025-05-15 — 1 day before Kiewit Infrastructure West Co. was awarded a $218M Department of the Interior Contract.
Rep. Rob Bresnahan sold $15,001 - $50,000 in $UNH on 2025-05-15 — 6 days before the Association Health Plans Act (S1847) was introduced, a bill that could increase competition for large health insurers.
Rep. Rob Bresnahan sold $1,001 - $15,000 in $CVS on 2025-05-15 — 6 days before the Association Health Plans Act (S1847) was introduced, a bill that could increase competition for large health insurers.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $AMD | Advanced Micro Devices, Inc. (AMD) | $15K-$50K | $114.99 | $347.81 | +202.5% | May 15, 2025 |
| BUY | $COP | ConocoPhillips Common Stock (COP) | $15K-$50K | $92.96 | — | — | May 15, 2025 |
| BUY | $PFE | Pfizer, Inc. Common Stock (PFE) | $15K-$50K | $22.60 | $27.00 | +19.5% | May 15, 2025 |
| BUY | $TXN | Texas Instruments Incorporated - Common Stock (TXN) | $15K-$50K | $187.83 | — | — | May 15, 2025 |
| BUY | $TMO | Thermo Fisher Scientific Inc Common Stock (TMO) | $15K-$50K | $404.93 | — | — | May 15, 2025 |
| BUY | $A | Agilent Technologies, Inc. Common Stock (A) | $1K-$15K | $112.40 | — | — | May 15, 2025 |
| BUY | $AMCR | Amcor plc Ordinary Shares (AMCR) | $1K-$15K | — | — | — | May 15, 2025 |
| BUY | $CAT | Caterpillar, Inc. Common Stock (CAT) | $1K-$15K | $349.81 | — | — | May 15, 2025 |
| BUY | $GEHC | GE HealthCare Technologies Inc. - Common Stock (GEHC) | $1K-$15K | — | — | — | May 15, 2025 |
| BUY | $GIS | General Mills, Inc. Common Stock (GIS) | $1K-$15K | — | — | — | May 15, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Treat and Reduce Obesity Act of 2025
The Treat and Reduce Obesity Act of 2025 would mandate Medicare Part D coverage of GLP-1 obesity drugs, unlocking a massive new payer market of ~27 million beneficiaries. $NVO and $LLY are the two direct beneficiaries. The bill is in early-stage committee referral with 22 bipartisan cosponsors; no companion bill has passed the House yet. Real market data shows $NVO gaining 15.56% over 30 days vs $LLY's +0.7%, suggesting the market may be overweighting Novo's near-term Medicare exposure given its larger U.S. obesity market share.
DeOndra Dixon INCLUDE Project Act of 2025
HR3491 (DeOndra Dixon INCLUDE Project Act) authorizes a Down syndrome research program at NIH but appropriates zero funding. With only 5 procedural actions over a year and stalled committee markup, the bill has no near-term market impact. No public companies are directly affected.
Improving Seniors’ Timely Access to Care Act of 2025
The Improving Seniors' Timely Access to Care Act mandates electronic prior authorization for all Medicare Advantage plans by 2028, forcing a regulatory-driven health IT spending wave. Oracle (ORCL) is the clearest beneficiary as dominant EHR vendor, while major MA insurers (UNH, ELV, HUM, CVS) face mandated IT investment but gain long-term operational efficiency. The bill has strong bipartisan momentum with 68 cosponsors and an identical House companion.
Expanding Access to Diabetes Self-Management Training Act of 2025
HR3826 expands Medicare coverage of diabetes self-management training, removing hour limits and testing virtual delivery. This structurally increases the diagnostically engaged Medicare beneficiary pool, directly benefiting CGM makers ($DXCM, $ABT) and insulin pump manufacturers ($MDT). The bill is early-stage but has a Senate companion and bipartisan sponsorship, and current stock prices for all three tickers are near 52-week lows, potentially discounting this structural catalyst.
Supporting Healthy Moms and Babies Act
The 'Supporting Healthy Moms and Babies Act' (HR3762) is an early-stage bill that would mandate comprehensive maternity/newborn care coverage without cost-sharing under ACA plans. With 28 cosponsors, a companion bill in the Senate, and referral to three committees, legislative progress is early but has nominal bipartisan support. Insurers UNH and CI face increased medical costs, while diagnostic labs LH and DGX benefit from higher utilization. No dollar amount is authorized or appropriated.
KIEWIT INFRASTRUCTURE WEST CO.: $218M Department of the Interior Contract
This $218M contract for wastewater treatment facility rehabilitation in Yosemite National Park is a significant win for Kiewit Infrastructure West Co., a private entity, but directly benefits publicly traded infrastructure and utility companies in its supply chain. The award aligns with recent legislative efforts to bolster water infrastructure, suggesting a positive outlook for the sector.
Association Health Plans Act
S.1847 is an early-stage bill expanding self-funded association health plans for small businesses, structurally negative for fully insured commercial carriers. The bill has no dollar authorization and remains in committee with only 6 sponsors — near-term passage probability is low. Real market data shows large health insurers (UNH, HUM, CVS, CNC) surging 15-55% in the last 30 days, but this rally is unrelated to S.1847 and driven by broader sector dynamics.
CARGO Act of 2025
The CARGO Act of 2025, an early-stage Senate bill, would ban NIH funding for animal research conducted outside the U.S., redirecting $2.2B from international to domestic facilities. Over the past 7 days, $CRL has fallen -2.88% and $IQV has fallen -1.6%, reflecting the market pricing in this legislative headwind for CROs with international exposure.
Access Technology Affordability Act of 2025
S. 1918 is an early-stage, low-probability bill proposing a refundable tax credit for blind individuals purchasing access technology. It creates no direct revenue stream for any public company and has negligible near-term market impact.
SEPSIS Act
The SEPSIS Act (S.1929) is an early-stage authorization bill that would create federal programs for sepsis research, education, and data collection. It authorizes but does not appropriate funding, and with only 6 cosponsors and referral to committee in June 2025, passage remains uncertain. Real market data shows all four diagnostic/lab stocks have declined 1-6% in the past week and 2-10% over 30 days, reflecting broader market pressure on healthcare despite the legislative catalyst.
Other Filings by Rob Bresnahan
Free — no credit card
Get the next Bresnahan trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.